Repression of allo-cell transplant rejection through CIITA ribonuclease P+ hepatocyte

World J Gastroenterol. 2003 May;9(5):1077-81. doi: 10.3748/wjg.v9.i5.1077.

Abstract

Aim: Allo-cell transplant rejection and autoimmune responses were associated with the presence of class II major histocompatibility complex (MHC II) molecules on cells. This paper studied the effect of Ribonuclease P (RNase P) against CIITA, which was a major regulator of MHCII molecules, on repressing the expression of MHCII molecules on hepatocyte.

Methods: M1-RNA is the catalytic RNA subunit of RNase P from Escherichia coli. It were constructed that M1-RNA with guide sequences (GS) recognizing the 452, 3408 site of CIITA by PCR from pTK117 plasmid, then were cloned into the EcoRI/BglII or EcoR//SalIsite of vector psNAV (psNAV-M1-452-GS, psNAV-M1-3408-GS) respectively. The target mould plate (3176-3560) of CIITA was obtained from Raji cell by RT-PCR, and then inserted into the XhoI/EcoRIof pGEM-7zf(+) plasmid (pGEM-3176). These recombinant plasmids were screened out by sequence analysis. psNAV-M1-452-GS, psNAV-M1-3408-GS and its target RNA pGEM-3176 were transcribed and then mixed up and incubated in vitro. It showed that M1-3408-GS could exclusively cleave target RNA that formed a base pair with the GS. Stable transfectants of hepatocyte cell line with psNAV-M1-3408-GS were tested for expression of class II MHC through FCM, for mRNA abundance of MHCII, Ii and CIITA by RT-PCR., for the level of IL-2 mRNA on T cell by mixed lymphocyte reaction.

Results: When induced with recombinant human interferon-gamma (IFN-gamma), the expression of HLA-DR, -DP, -DQ on psNAV-M1-3408-GS(+) hepatocyte was reduced 83.27 %, 88.93 %, 58.82 % respectively, the mRNA contents of CIITA, HLA-DR, -DP, -DQ and Ii decreased significantly. While T cell expressed less IL-2 mRNA in the case of psNAV-M1-3408-GS(+) hepatocyte.

Conclusion: The Ribonuclease P against CIITA-M1-3408-GS could effectively induce antigen-specific tolerance through cleaving CIITA. These results provided insight into the future application of M1-3408-GS as a new nucleic acid drug against allo-transplantation rejection and autoimmune diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Cell Line
  • DNA / genetics
  • Endoribonucleases / genetics
  • Endoribonucleases / metabolism*
  • Escherichia coli Proteins*
  • Graft Rejection / enzymology
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Hepatocytes / enzymology
  • Hepatocytes / immunology
  • Hepatocytes / transplantation*
  • Histocompatibility Antigens Class II / metabolism
  • Humans
  • Interferon-gamma / biosynthesis
  • Interleukin-2 / genetics
  • Liver, Artificial
  • Lymphocyte Culture Test, Mixed
  • Nuclear Proteins*
  • RNA, Catalytic / genetics
  • RNA, Catalytic / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Ribonuclease P
  • Tissue Engineering
  • Trans-Activators / genetics
  • Trans-Activators / metabolism*
  • Transfection
  • Transplantation, Homologous

Substances

  • Escherichia coli Proteins
  • Histocompatibility Antigens Class II
  • Interleukin-2
  • MHC class II transactivator protein
  • Nuclear Proteins
  • RNA, Catalytic
  • RNA, Messenger
  • Trans-Activators
  • Interferon-gamma
  • DNA
  • Endoribonucleases
  • RPP14 protein, human
  • Ribonuclease P
  • ribonuclease P, E coli